Loading provider…
Loading provider…
Hematology & Oncology Physician in Chico, CA
NPI: 1043287378Primary Practice Location
ENLOE HEALTH
1531 Esplanade, Chico, CA
Primary Employer
Enloe Specialty Physicians, Inc
enloe.org
HQ Phone
Get MD Sam's Phone Numberphone_androidMobile
Get MD Sam's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2004 - 2026
FL State Medical License
2003 - 2006
CT State Medical License
2003 - 2004

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
Zucker School of Medicine at Hofstra/Northwell
Fellowship • Hematology and Medical Oncology
2002 - 2005
New York-Presbyterian/Queens
Residency • Internal Medicine
1999 - 2002
Uludag University FOM
Medical School
Until 1997
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 588 | 1,354 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 520 | 1,697 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 91 | 101 |
| 4 | G2212Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 65 | 97 |
| 5 | 99223Initial hospital inpatient care, typically 70 minutes per day | 24 | 30 |
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, OTHER: Laboratory Biomarker Analysis, BIOLOGICAL: Ipilimumab, OTHER: Quality-of-Life Assessment
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, DRUG: Taselisib
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Docetaxel, OTHER: Laboratory Biomarker Analysis, DRUG: Palbociclib